Positioning Statement
Latest News

BIO Ventures for Global Health

Impacting global health through multi-stakeholder initiatives, high impact partnering, and alliance management.

BVGH has a unique perspective: we look at the health problems facing developing countries and emerging markets through a dual lens with expertise in both global health and biopharmaceutical industry dynamics.

For more information about BVGH, services offered, or current programs download the brochure.

BVGH Brochure

Biopharma Companies Fight Tropical Diseases to Improve Global Health

Neglected tropical diseases (NTDs) are a group of devastating viral, bacterial, and parasitic diseases that predominantly burden individuals and communities living in poverty. NTDs received the moniker “neglected” due to the lack of attention they have received [...]

BVGH Congratulates Liberia on Ending Ebola Epidemic

BIO Ventures for Global Health (BVGH) President Jennifer Dent today praised Liberia’s successful campaign to curb the recent Ebola virus disease (EVD) outbreak. The World Health Organization declared Liberia to be free of the devastating virus for a second time on September 3rd. [...]

Takeda joins WIPO Re:Search to Accelerate R&D of New Drugs for Neglected Tropical Diseases, Malaria and TB

Takeda Pharmaceutical Company Limited today announced its participation in WIPO Re:Search, a consortium to accelerate research and development (R&D) of new drugs, vaccines, and diagnostics for neglected tropical diseases, malaria and tuberculosis (TB) [...]

Global Health at the Crossroad of Industry and Science

If rainy season in Southeast Asia comes early—as it has this year and steadily has for the last several—so does the Aedes aegypti mosquito, and the dengue virus it carries. In 2013, severe dengue seized Thailand’s people and strained government resources when the country saw 140,000 dengue cases and 129 deaths, the country’s []

Kineta Awarded NIH/NIAID Contract to Develop New Therapies for Viral Diseases

BVGH Membership Program member, Kineta, Inc. has been awarded an NIH/NIAID research contract to develop new therapies for viral pathogens such as Ebola, influenza A and B, dengue, West Nile, and Lassa viruses, among others. Kineta’s novel antiviral therapy works by activating the human host’s innate immune response to viruses. Click here to read Kineta’s press release.